# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-052289
Filing Date
2022-04-28
Accepted
2022-04-28 16:23:24
Documents
4
Period of Report
2022-06-02

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | tm223576-1_def14a.htm | DEF 14A | 1068631
2 | GRAPHIC | lg_akerotherepeatics-4c.jpg | GRAPHIC | 34539
3 | GRAPHIC | tm223576d1-px_akeropg1bw.jpg | GRAPHIC | 573054
4 | GRAPHIC | tm223576d1-px_akeropg2bw.jpg | GRAPHIC | 427181
| Complete submission text file | 0001104659-22-052289.txt |  | 2494154

Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38944 | Film No.: 22866996
SIC: 2834 Pharmaceutical Preparations